Doctorglasses Chain Co Ltd (300622) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Doctorglasses Chain Co Ltd ¥14.63, price ¥15.65, upside -6.5%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Doctorglasses Chain Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥6.12 – ¥31.82 · fair‑value band ¥10.98 – ¥18.29 · the ¥15.65 price screens above the ¥14.63 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Doctorglasses Chain Co in your weekly email
Every Wednesday you see whether Doctorglasses Chain Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Doctorglasses Chain Co.,Ltd. engages in the retail of eyewear in China. It offers optical glasses; smart glasses; ready-to-wear glasses series, including sunglasses, reading glasses, etc.; contact lenses; soft/hard contact lenses; care solutions, and eye health peripheral products.
Show more
Doctorglasses Chain Co.,Ltd. engages in the retail of eyewear in China. It offers optical glasses; smart glasses; ready-to-wear glasses series, including sunglasses, reading glasses, etc.; contact lenses; soft/hard contact lenses; care solutions, and eye health peripheral products. The company provides eye examinations and fitting, wearing, and debugging, to after-sales visit. It sells its products through its store brands comprising doctor glasses, President Optical, Boojing, zèle, Concrete, and ZORRO, as well as through e-commerce and franchise channels. Doctorglasses Chain Co.,Ltd. was founded in 1993 and is headquartered in Shenzhen, China.
Stock analysis
Doctorglasses Chain Co Ltd (300622) currently trades at ¥15.65, while our model-based Fair Value estimate is ¥14.63, implying the stock looks roughly 7.0% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥14.31 per share, and 5 of the 24 models we run sit above the ¥15.65 price.
Bear case: the Asset-Based group reads lowest at ¥1.91, and 19 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥10.98 (bear) to ¥18.29 (bull), the price of ¥15.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Consumer Cyclical sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Doctorglasses Chain Co Ltd reported revenue of 1.4B CNY in FY2025 versus 887M CNY in FY2021, a compound +11.3%/yr. Reported net income was 149M CNY in FY2025, compounding +11.9%/yr from FY2021.
Key figures
Market cap 5.0B CNY (≈ $745M) · P/E ratio 31.9 · P/S ratio 3.49 · EPS (TTM) ¥0.4900 · Dividend yield 12.3% · Net margin 10.9% · Return on equity 18.6% · Return on assets (EBIT) 12.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −1% fair-value upside, at −7%, 300622 screens richer than that median.
Fair Value models
Bear ¥10.98Fair Value ¥14.63Bull ¥18.29
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Start year 2020 (pandemic). Over 10 years: +13.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.6%
Dividend (yield on the price)12.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3% vs 5%, steady
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 14%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +6.6% a year for the price.
Compare Doctorglasses Chain Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Retail · 231 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−7% · Below median
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)11% · Top 25%
Operating margin (TTM)14% · Top 25%
Growth and dividend
Revenue growth8% · Above median
Dividend yield (TTM)12.3% · Top 25%
Valuation Multiplesvs Specialty Retail median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Doctorglasses Chain Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300622
Frequently asked questions
Is Doctorglasses Chain Co Ltd (300622) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥14.63 versus a price of ¥15.65, about −7% upside (fairly valued).
What is the fair value of 300622?
Our model-based fair value for Doctorglasses Chain Co Ltd is ¥14.63 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥15.65.
What is the quality score of 300622?
Doctorglasses Chain Co Ltd has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Doctorglasses Chain Co Ltd (300622)?
Our model-based price target is the fair value of ¥14.63 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario ¥10.98, optimistic scenario ¥18.29. It is a calculation from audited fundamentals, not an analyst target.
What is the Doctorglasses Chain Co Ltd stock forecast for 2026?
Our models put fair value at ¥14.63, about −7% upside versus a price of ¥15.65 (fairly valued). Cautious scenario ¥10.98, optimistic scenario ¥18.29. The calculation is refreshed regularly with new filings.
What is the revenue of Doctorglasses Chain Co Ltd (300622)?
Doctorglasses Chain Co Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Sep 23, 2026).
Does Doctorglasses Chain Co Ltd pay a dividend?
Doctorglasses Chain Co Ltd currently shows a dividend yield of about 12.33% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Doctorglasses Chain Co Ltd (300622)?
For today's price to be fair in a discounted-cash-flow model, Doctorglasses Chain Co Ltd would have to grow free cash flow by +8.3 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 300622 use?
Our models discount Doctorglasses Chain Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.06, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Doctorglasses Chain Co Ltd that is +8.3 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Doctorglasses Chain Co Ltd (300622) delivered so far?
Over the past 5 years revenue at Doctorglasses Chain Co Ltd grew +15.7 % a year. The price currently implies +8.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Doctorglasses Chain Co Ltd (300622) growing?
The median revenue growth in the sector is +2.5 % a year. That is the yardstick for the growth priced into Doctorglasses Chain Co Ltd (+8.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Doctorglasses Chain Co Ltd (300622)?
The free-cash-flow yield on the price is 5.53 %: that much free cash flow Doctorglasses Chain Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Doctorglasses Chain Co Ltd (300622)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Doctorglasses Chain Co Ltd it is ¥14.63 per share (as of Sep 23, 2026), against a price of ¥15.65. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Doctorglasses Chain Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 300622 trades above its calculated fair value: price ¥15.65, fair value ¥14.63, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300622?
No. The price is what the market pays today (¥15.65); the fair value is what the company's own numbers justify (¥14.63). For Doctorglasses Chain Co Ltd the two are ¥1.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Doctorglasses Chain Co Ltd worth?
The market values Doctorglasses Chain Co Ltd at about 5.0B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥15.65; our models calculate a fair value of ¥14.63 per share.
What do the bullish and bearish scenarios say about 300622?
Our models span a range for Doctorglasses Chain Co Ltd: cautious scenario ¥10.98, base ¥14.63, optimistic ¥18.29 per share (as of Sep 23, 2026, price ¥15.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300622?
Doctorglasses Chain Co Ltd trades at a price-to-earnings ratio of 31.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥14.63 is built from several models across several years. Other multiples: P/B 5.5, P/S 3.6, EV/EBITDA 25.2.
How solid is the balance sheet of Doctorglasses Chain Co Ltd (300622)?
Balance-sheet figures for Doctorglasses Chain Co Ltd (as of Sep 23, 2026): return on equity 18.6%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 300622 from its 52-week high?
Doctorglasses Chain Co Ltd trades at ¥15.65, about 40% below its 52-week high of ¥26.19 and 15% above the low of ¥13.65 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥14.63 is for.
Which stocks are comparable to Doctorglasses Chain Co Ltd?
From the same area (Consumer Cyclical) we also value Alimentation Couche-Tard Inc, Casey's General Stores, Inc, Williams-Sonoma, Inc, Ulta Beauty, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Doctorglasses Chain Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥15.65, calculated fair value ¥14.63 (−7%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300622 calculated?
We run Doctorglasses Chain Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥14.63, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Doctorglasses Chain Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Doctorglasses Chain Co Ltd (300622)?
The closing price on Sep 22, 2026 was ¥15.65. Our model-based fair value is ¥14.63, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Doctorglasses Chain Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Doctorglasses Chain Co Ltd (300622) come from?
Earnings per share at Doctorglasses Chain Co Ltd grew +9.1 % a year from 2013 to 2024. Broken into its drivers: revenue per share +9.6 %, EBIT margin −1.4 %, tax rate +1.1 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Doctorglasses Chain Co Ltd
How large is the market capitalisation of Doctorglasses Chain Co Ltd (300622)?
The market capitalisation of Doctorglasses Chain Co Ltd is 5.0B CNY (≈ $745M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Doctorglasses Chain Co Ltd (300622)?
The price-to-sales ratio of Doctorglasses Chain Co Ltd is 3.49 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Doctorglasses Chain Co Ltd (300622)?
Earnings per share at Doctorglasses Chain Co Ltd are ¥0.4900 (price ÷ EPS = P/E 31.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Doctorglasses Chain Co Ltd (300622)?
The dividend yield of Doctorglasses Chain Co Ltd is 12.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Doctorglasses Chain Co Ltd (300622)?
The net margin of Doctorglasses Chain Co Ltd is 10.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Doctorglasses Chain Co Ltd (300622)?
The return on equity (ROE) of Doctorglasses Chain Co Ltd is 18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Doctorglasses Chain Co Ltd (300622)?
On an EBIT basis the return on assets of Doctorglasses Chain Co Ltd is 12.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Doctorglasses Chain Co Ltd (300622)?
The operating margin of Doctorglasses Chain Co Ltd is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Doctorglasses Chain Co Ltd (300622)?
Revenue at Doctorglasses Chain Co Ltd is growing +8.3% versus a year earlier (3y avg +12.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Doctorglasses Chain Co Ltd (300622)?
Earnings per share at Doctorglasses Chain Co Ltd are growing +30.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Doctorglasses Chain Co Ltd (300622) hold?
Doctorglasses Chain Co Ltd holds more cash than debt, 28.9M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Doctorglasses Chain Co Ltd in the live analysis
One click puts Doctorglasses Chain Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
